A first NZ study looked at the role of Lutetium-177-PSMA I & T in the progression of mCRPC
Loading...
Supplementary material
Other Title
Authors
Vyas, Madhusudan
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2022-07-23
Supervisors
Type
Conference Contribution - Oral Presentation
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
New Zealand
cancer patients
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC
cancer patients
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC
ANZSRC Field of Research Code (2020)
Citation
Vyas, Madhusudan. (2022, July). A first NZ Study Looked at the Role of Lutetium-177-PSMA I & T in the Progression of mCRPC. Paper presented at the Auckland/Northland Branch NZIMRT, Auckland University Medical School, Auckland.
Abstract
OBJECTIVES
To assess the efficacy of Lutetium-177-PSMA-I&T therapy to palliate end stage mCRPC
To review tolerability and impact on QOL of Lutetium-177- PSMA-I&T therapy
Publisher
Permanent link
Link to ePress publication
DOI
Copyright holder
Author
Copyright notice
All rights reserved